Looks like you’re on the UK site. Choose another location to see content specific to your location
PerkinElmer assay shows benefits in helping to prevent preeclampsia
PerkinElmer has highlighted the findings of a new study that demonstrate the role its Delfia Xpress PlGF 1-2-3 assay can play in the prevention of preterm preeclampsia.
The assay was utilised in a recent study by the Fetal Medicine Foundation, which indicated that administering low-dose aspirin led to a 62 percent reduction in the rate of preterm preeclampsia and an 82 percent reduction in cases of early preeclampsia.
Researchers selected the Delfia Xpress PlGF 1-2-3 assay for use in the study based on its proven performance in predicting preeclampsia during the first trimester. It was shown to be effective in identifying women at high risk of the condition who would benefit from low-dose aspirin treatment throughout their pregnancy.
Based on the results, the researchers recommended that this screening test should now become the new standard of care in all countries.
Prahlad Singh, senior vice-president and president of diagnostics at PerkinElmer, said: "With this latest research underscoring the need for first trimester screening for preeclampsia, we are committed to working with governmental bodies and professional organisations to help implement this critical prenatal test for the benefit of all pregnant women."
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard